The aim was to evaluate the potential of KL-6 as a biomarker in routine clinical practice as early as the first two weeks of life and to improve the current risk stratification for the development of BPD in EPIs less than 28 GA. Here, MUC1 is linked to bronchopulmonary dysplasia.